Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Bendeka is a prescription cancer medicine containing bendamustine hydrochloride, an alkylating drug. It is approved for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma that progressed during or within six months of rituximab or a rituximab-containing regimen. Bendeka is supplied as a concentrated liquid that is diluted before intravenous infusion.
read more about bendeka ...Bendamustine forms reactive alkyl groups that bind to DNA and create interstrand DNA crosslinks. These abnormal links interfere with normal DNA structure and cellular processes and can lead to cell death. Bendamustine has activity against both resting and dividing cells, although its exact anticancer mechanism is not fully defined.
Bendeka is approved for chronic lymphocytic leukemia. It is also approved for indolent B-cell non-Hodgkin lymphoma that progressed during or within six months after treatment with rituximab or a rituximab-containing regimen. Its comparative efficacy against first-line chronic lymphocytic leukemia treatments other than chlorambucil has not been established.
For chronic lymphocytic leukemia, the labeled dose is 100 mg per square meter by intravenous infusion over 10 minutes on days 1 and 2 of a 28-day cycle for up to six cycles. For indolent B-cell non-Hodgkin lymphoma, the dose is 120 mg per square meter on days 1 and 2 of a 21-day cycle for up to eight cycles.
Bendeka can cause severe bone marrow suppression, serious infections, progressive multifocal leukoencephalopathy, infusion reactions, anaphylaxis, tumor lysis syndrome, severe skin reactions, liver injury, secondary cancers, and fetal harm. Blood counts are checked frequently during treatment. Liver tests and the infusion site also require monitoring during therapy.
Bendeka contains bendamustine hydrochloride, an alkylating cancer medicine that damages DNA in susceptible cells.
Bendeka treats chronic lymphocytic leukemia and selected indolent B-cell non-Hodgkin lymphoma.
Each labeled Bendeka dose is infused intravenously over 10 minutes after dilution.
Yes. Severe bone marrow suppression can occur, so white cells, platelets, hemoglobin, and neutrophils are checked frequently.
BENDEKA (bendamustine hydrochloride) Prescribing Information. https://www.bendekahcppp.tevapharm.com/globalassets/bendeka-hcp/prescribinginformation.pdf. Date Accessed September 15, 2026.
Bendamustine Hydrochloride. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/bendamustinehydrochloride. Date Accessed September 15, 2026.
Bendamustine Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a608034.html. Date Accessed September 15, 2026.
DailyMed - BENDEKA (bendamustine hydrochloride) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ace9a43b-f9bd-4896-abfe-0ef4fec67ddf. Date Accessed September 15, 2026.
Definition of Bendamustine Hydrochloride. NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bendamustine-hydrochloride. Date Accessed September 15, 2026.